Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions

Rhea-AI Summary

Daxor (Nasdaq: DXR) will exhibit at the American College of Cardiology Annual Scientific Session (ACC.26) in New Orleans, March 28–30, 2026, at Booth #1557. The company will showcase its new portable Blood Volume Analyzer (BVA), an FDA-cleared diagnostic that directly quantifies total blood, plasma, and red cell volume with >95% accuracy.

According to the company, peer-reviewed studies show BVA-guided care produced a 56% reduction in 30-day readmissions and an 82% reduction in 30-day mortality; Daxor highlights BVA as a tool to optimize fluid management and reduce the $3.5 billion annual Medicare heart-failure readmission burden.

News Market Reaction – DXR

+0.18%

1 alert

+0.18% News Effect

On the day this news was published, DXR gained 0.18%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Diagnostic accuracy: >95% accurate Medicare readmission burden: $3.5 billion 30-day readmission reduction: 56% reduction +3 more

6 metrics

Diagnostic accuracy >95% accurate BVA direct quantification of blood, plasma, red cell volume

Medicare readmission burden $3.5 billion Annual U.S. Medicare burden of heart failure readmissions

30-day readmission reduction 56% reduction BVA-guided care impact on 30-day readmissions in studies

30-day mortality reduction 82% reduction BVA-guided care impact on 30-day mortality in studies

Conference dates March 28–30, 2026 ACC.26 Annual Scientific Session schedule

Booth number #1557 Daxor exhibit location at ACC.26

Market Reality Check

Price: $11.12 Vol: Volume 14,310 versus 20-d...

normal vol

$11.12 Last Close

Volume Volume 14,310 versus 20-day average 11,292 (relative volume 1.27) shows slightly elevated interest pre-announcement. normal

Technical Price at 11.37 is trading just below the 200-day MA of 11.52, near longer-term trend levels.

Peers on Argus

DXR slipped 0.96% while peers were mixed: AKYA -8.51%, ZJYL +17.21%, ZTEK -1.14%...

DXR slipped 0.96% while peers were mixed: AKYA -8.51%, ZJYL +17.21%, ZTEK -1.14%, PDEX +2.31%, MLSS -6.85%, suggesting stock-specific dynamics rather than a unified sector move.

Historical Context

5 past events · Latest: 2026-03-10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2026-03-10	Conference product debut	Positive	+1.6%	Announced debut of rapid portable blood volume analyzer at SCCM 2026 conference.
2026-03-09	Investor conference	Neutral	-0.7%	CEO participation in virtual Alpha Best Ideas conference with presentation and 1x1 meetings.
2026-03-03	Corporate update letter	Positive	-0.9%	Shared 2025 transformation, FDA clearance, 45% revenue growth and capital raise details.
2026-03-03	Fiscal year results	Positive	-0.9%	Reported 45% revenue growth, higher NAV, FDA clearance and $9M direct offering.
2026-02-24	Outpatient expansion	Positive	-1.7%	Launched BVA diagnostic program in Tennessee expanding outpatient cardiology presence.

Pattern Detected

Recent DXR news has been largely positive on product, growth, and capital raises, yet price reactions often skew modestly negative, indicating a tendency for shares to underreact or sell off on good news.

Recent Company History

Over the last few weeks, Daxor highlighted FDA 510(k) clearance for its next‑generation portable Blood Volume Analyzer, reported 45% operating revenue growth and rising net asset value, expanded its outpatient BVA diagnostic program, and announced a $9.0M registered direct offering. It also promoted upcoming conference appearances and product debuts. This ACC.26 exhibition news continues the theme of commercial rollout and clinical positioning for its portable BVA platform, building on prior approvals, capital raising, and deployment updates.

Market Pulse Summary

This announcement spotlights Daxor’s next-generation portable Blood Volume Analyzer, emphasizing >95...

Analysis

This announcement spotlights Daxor’s next-generation portable Blood Volume Analyzer, emphasizing >95% accuracy and peer-reviewed data showing 56% lower 30‑day readmissions and 82% lower 30‑day mortality with BVA‑guided care. Showcasing the device at ACC.26 supports its positioning in cardiology settings. In context of recent FDA 510(k) clearance, revenue growth, and outpatient expansion, investors may watch for metrics on hospital adoption, reimbursement utilization, and real-world outcomes from broader deployment.

Key Terms

blood volume analyzer, fda-cleared diagnostic, plasma, peer-reviewed studies

4 terms

blood volume analyzer medical

"Daxor will showcase its new, rapid, portable Blood Volume Analyzer (BVA)."

A blood volume analyzer is a medical device that measures how much blood is circulating in a patient’s body, often used to guide treatment for conditions like heart failure, dehydration, or during surgery. For investors, it matters because demand, regulatory approval, reimbursement and clinical acceptance determine whether the device will generate steady sales—think of it as a reliable fuel gauge for doctors, where wider adoption can signal predictable revenue and market growth.

fda-cleared diagnostic regulatory

"As the only FDA-cleared diagnostic providing greater than 95% accurate, direct quantification"

A FDA-cleared diagnostic is a medical test or device that U.S. regulators have reviewed and allowed to be marketed for a specific use after determining it meets agency standards for safety and performance. Think of it like a product passing a trusted safety and usefulness inspection before store shelves; for investors, clearance reduces regulatory risk, helps access customers and reimbursements, and can be an important step toward commercial revenue growth.

plasma medical

"direct quantification of a patient’s total blood, plasma, and red cell volume"

Plasma is the pale yellow liquid portion of blood that carries proteins, antibodies and other components which can be separated and processed into therapies, diagnostic products and vaccines. For investors, plasma functions like a raw material: its supply, collection costs, quality controls and regulatory oversight directly affect revenue, margins and growth prospects for companies that collect plasma or make plasma-derived products.

peer-reviewed studies medical

"Peer-reviewed studies demonstrate that BVA-guided care results in a 56% reduction"

Research papers that are evaluated and approved by independent experts in the same field before publication. This outside check is like having referees verify a game’s score: it doesn’t guarantee results are final, but it reduces obvious errors, bias, or flawed methods. Investors rely on peer-reviewed studies because they carry more credibility when assessing a company’s product claims, regulatory prospects, or scientific risks.

AI-generated analysis. Not financial advice.

Oak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the American College of Cardiology (ACC.26) Annual Scientific Session in New Orleans, LA, March 28–30, 2026.

Daxor will showcase its new, rapid, portable Blood Volume Analyzer (BVA). As the only FDA-cleared diagnostic providing greater than 95% accurate, direct quantification of a patient’s total blood, plasma, and red cell volume, the BVA replaces subjective guesswork with definitive data. This precision is a critical benefit of BVA, particularly for health systems navigating the $3.5 billion annual Medicare burden of heart failure readmissions in the United States.

“The most expensive patient is the one who comes back,” said Michael Feldschuh, Daxor CEO and President. “Our BVA system replaces clinical guesswork with objective data, allowing teams to optimize fluid management and discharge timing. Peer-reviewed studies demonstrate that BVA-guided care results in a 56% reduction in 30-day readmissions and an 82% reduction in 30-day mortality, delivering a transformative value proposition that aligns the interests of clinicians, hospital administrators, and payers alike.”

Daxor is exhibiting at Booth #1557, where it will demonstrate how its portable technology is poised to scale across inpatient and outpatient care environments.

About American College of Cardiology

The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. As the preeminent source of professional medical education for the entire cardiovascular care team since 1949, ACC credentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards, and guidelines. Through its world-renowned family of JACC Journals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes. Learn more at www.ACC.org.

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.

For more information, please visit our website at Daxor.com.

Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com

FAQ

What will Daxor (DXR) present at ACC.26 on March 28–30, 2026?

Daxor will demonstrate its new portable Blood Volume Analyzer (BVA) at ACC.26, Booth #1557. According to the company, the BVA is FDA-cleared and designed for rapid, point-of-care quantification of total blood, plasma, and red cell volume to guide fluid management.

How accurate is Daxor's BVA that DXR is showcasing at ACC.26?

The BVA is described as greater than 95% accurate for direct blood volume measurement. According to the company, this FDA-cleared accuracy replaces clinical guesswork with objective volume data for inpatient and outpatient decision-making.

What clinical outcomes does Daxor (DXR) cite for BVA-guided care?

According to the company, peer-reviewed studies report a 56% reduction in 30-day readmissions and an 82% reduction in 30-day mortality with BVA-guided care. These figures are presented as evidence of BVA's potential to improve heart-failure outcomes.

How might DXR's BVA affect hospital readmissions and costs?

Daxor positions the BVA as reducing preventable readmissions tied to heart failure, citing a $3.5 billion annual Medicare readmission burden. According to the company, objective volume data helps optimize discharge timing and fluid management to lower readmissions and costs.

Where and when can investors see Daxor (DXR) demonstrate the portable BVA?

Investors can visit Daxor at ACC.26 in New Orleans, March 28–30, 2026, at Booth #1557. According to the company, live demonstrations will show the portable system's workflow for inpatient and outpatient settings.

Does Daxor (DXR) claim FDA clearance for the portable BVA being shown at ACC.26?

Yes; according to the company, the portable BVA is FDA-cleared for direct blood, plasma, and red cell volume measurement. The company states this clearance supports clinical use across care settings to inform fluid management decisions.